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Abstract 
 
Heart rate variability (HRV) is a useful index of autonomic function and has been 
linked to the development of high altitude (HA) related illness. However, its 
assessment at HA has been undermined by the relative expense and limited portability 
of traditional HRV devices which have mandated at least a five minute heart rate 
recording. In this study the portable ithlete™ HRV system, which uses a 55 second 
recording, was compared with a reference method of HRV which utilises  a five 
minute electrocardiograph recording (CheckMyHeart™). The root mean squares of 
successive R-R intervals (RMSSD) for each device was converted to a validated HRV 
score (lnRMSSDx20) for comparison. Twelve healthy volunteers were assessed for 
HRV using the two devices across seven time points at HA over 10 days. There was 
no significant change in the HRV values with either the ithlete (P=0.3) or the 
CheckMyHeart™ (p=0.19) device over the seven altitudes. There was also a strong 
overall correlation between the ithlete™ and CheckMyHeart™ device (r=0.86; 95% 
confidence interval: 0.79 to 0.91). The HRV was consistently, though non-
significantly higher with ithlete™ than with the CheckMyHeart™ device (mean 
difference [bias] 1.8l; 95% CI -12.3 to 8.5). In summary the ithlete™ and 
CheckMyHeart™ system provide relatively similar results with good overall 
agreement at HA.   
 
 
 
  
1. Introduction 
The autonomic nervous system (ANS) plays a pivotal role in the regulation of a 
number of physiological processes. ANS control of the heart via both sympathetic and 
parasympathetic ANS innervation leads to continuous beat to beat deviations in heart 
rate and RR intervals which can be quantified as changes in heart rate variability 
(HRV) (Weimer, 2010). Hence, quantification of HRV is an important method of 
assessing ANS function in vivo. It has been shown that a number of factors such as 
inter-current illness, cardiovascular disease, physical overtraining and even mental 
stress can lead to increased cardiac sympathetic activation and a reduction in HRV 
(Lahiri et al., 2008; Kiviniemi AM et al., 2014; Sassi et al., 2015). This has led to a 
number of useful clinical applications in the field of sport and exercise medicine such 
as the assessment of physical fitness and overtraining as well as competitive readiness 
(Da Silva et al., 2015; Routledge et al., 2010; D'Ascenzi F et al., 2014; Kiviniemi AM  
et a.,l 2014).  
 
Traditional methods of HRV have required expensive and specialised equipment and 
processing software with the need to record the cardiac activity for at least five 
minutes (Task Force 1996). There have been significant recent technological 
advances with increasing miniaturization of available HRV devices that provide full 
disclosure single channel ECG recordings with internal software to provide accurate 
assessment of HRV.  Whilst considerably more affordable than traditional methods 
these devices are still relatively expensive, require the purchase of disposable ECG 
electrodes and may not be practical for everyday use. There has been a significant 
expansion in non-invasive HRV devices which utilise either finger sensors or chest 
straps which can wirelessly link to portable devices and mobile phones for data 
  
analysis.  They provide a portable, cheap and more practical method of assessing 
HRV. One of the key HRV parameters which is well suited to these ultra-portable 
HRV devices is the root mean square of successive R-R intervals (RMSSD). The 
RMSSD is a reliable time domain measure of vagally mediated cardiac control and 
parasympathetic activity (Task Force 2006). It has the advantage over several other 
HRV outputs in that it can be reliably assessed with ultrashort recordings, (over less 
<1 minute), improving its applicability and use compliance in athletes and others 
(Nussinovitch U et al., 2011; Nakamura et al., 2015; Esco and Flatt 2014; Flatt and 
Esco 2015). Moreover, the RMSSD appears to be less prone to the influence of 
respiration than many other HRV parameters and has been shown to be a robust 
marker of physical and mental stress (Grieco C et al., 2014; Saboul et al., 2013). The 
ithelte™ (HRV Fit Ltd, Southampton, UK) device is one of best known ultra-portable 
HRV devices which utilises a 55 second recording to provide a RMSSD derived HRV 
score. It has been shown to have excellent agreement (correlation coefficient of 0.99) 
with that obtained from a standard five minute electrocardiographic recording (Flatt 
and Esco 2013).  
 
Another area where HRV has been of increasing relevance has been in the field of 
high altitude (HA) medicine. There is increasing evidence to suggest that HA 
exposure leads to altered ANS activity and changes in HRV which may be linked to 
the development of acute mountain sickness (AMS) (Sevre  et al., 2001; Huang  et al., 
2010;  Karinen et al., 2012). The simplicity of the ithlete™ would circumvent many 
of the challenges faced by studying HRV at HA; however it has never been formally 
validated in this environment. In this study we sought to assess the ithlete™ HRV 
  
smart phone application in comparison with a reference electrocardiographic HRV 
device at HA.  
 
2. Materials and Methods  
2.1 Subjects  
This was a prospective observational study of 12 healthy British military servicemen 
and women on expedition to the Dhaulagiri region of the Himalayas in Nepal. All 
Subjects were studied on arrival at Kathmandu (1400m, day 0), at 1045m (day 2), 
1600m (day 3), 2050m (day 5), 2500m (day 6), 3100m (day 7) and 3600m (day 9).   
The study was approved by the Ministry of Defence Research and Medical Ethics. All 
participants underwent written informed consent. Resting recordings of oxygen 
saturations (SpO2) were performed using a Nellcor N-20P pulse oximeter (Nellcor 
Puritan Bennett, Coventry, UK). Baseline heart rate and blood pressure were 
measured  using an automated blood pressure cuff with the subject sat upright and 
rested for >10 minutes  (M6 Omron Healthcare, Milton Keynes, UK). Symptoms of 
acute mountain sickness were assessed using the Lake Louise Scoring system. The 
LLS scores allocates a score of 0–3 (symptom not present to severe) for symptoms of 
AMS (headache, gastrointestinal symptoms, fatigue/weakness, dizzy/light-
headedness, difficulty sleeping). A total score of >3 in the presence of a headache is 
consistent with AMS.  
 
2.2 Assessment of Heart Rate Variability  
Participants were all studied at approximately 0700 in the morning post micturition 
but prior to breakfast or caffeine. All subjects were seated, wearing warm clothing in 
  
a tent for at least 5 minutes before the HRV recordings were obtained (Flatt et al 
2013).   HRV variability was obtained using the ithlete™ (HRV Fit Ltd. 
Southampton, UK) and CheckMyHeart™ (CMH, Daily Care Biomedical, Taiwan) 
devices.  
 
For the ithlete™ each subject wore an elasticated chest strap heart rate monitor 
(Cardiosport Bluetooth) that was fastened securely around the upper thorax at the 
level of the xiphoid process. All ithlete™ HRV data was collected with the ithlete™ 
ECG receiver and ithlete™ application on the subjects apple smart phone as 
previously described (Flatt and Esco 2013). Two 55 second recordings were obtained 
with the ithlete during the first and last minute of a five minute HRV recording 
obtained by a CheckMyHeart™ device. During these ithlete™ recordings breathing 
prompts were followed and the average of the two ithlete™ readings were used. This 
prompt uses an animation to guide a control the overall breathing rate as well as the 
inspiratory and expiratory phases.  The CheckMyHeart™ HRV device is a validated 
battery powered portable HRV machine that utilises two skin ECG electrodes which 
were placed at the right sternal edge and over the apex beat to acquire a continuous 
five minute ECG recording for HRV as previously described (Wen et al 2007).  All 
stored recordings were later exported via USB hook up for full data analysis.  
 
The ithlete™ modifies the acquired RMSSD by taking the natural log transformation 
and multiplying by twenty (lnRMSSD × 20) to provide a more interpretable figure for 
the user on a ∼100 point scale (Wegerif, 2009). Hence this was also undertaken on 
the RMSSD data obtained from the CheckMyHeart™ device to compare with the 
ithlete™ as previously described (Flatt et al 2013).   
  
 
2.3 Statistical Analysis 
Data were analysed using GraphPad InStat version 3.05 and with all graphical figures 
presented using GraphPad Prism version 4.00 for Windows (GraphPad Software, San 
Diego, CA, USA; www.graphpad.com). The Kolmogorov-Smirnov test was 
undertaken to assess normality of all continuous data. The results were presented as 
mean ± standard deviation (SD). As the HRV data for both ithlete™ and 
CheckMyHeart™ were normally distributed paired comparisons of HRV measures 
were performed with a paired T test and correlations were quantified using the 
Pearson correlation coefficient ± 95% confidence interval (CI). Time dependent 
changes of continuous data within each group were assessed using repeated measures 
ANOVA and Tukey post-hoc test and the Friedman Test with the Dunn post-test for 
parametric and non-parametric data respectively. Comparison of HRV scores with 
increasing LLS Scores were assessed using the Kruskal-Wallis (nonparametric 
ANOVA) Test. Agreement in the paired sampling of the ithlete™ at the end of the 
first and fifth minute were assessed using the coefficient of variation and Pearson 
Correlation coefficient.  Agreements in HRV measurement between ithlete™ and 
CheckMyHeart™ were assessed using Bland-Altman plots (Bland and Altman., 1986) 
in which the difference between the two values were compared with the average 
values from the comparative two readings. The bias was defined as the mean ± SD of 
the difference between the readings. Reasonable agreement was defined as <5% of 
readings being within 1.96SD (95% CI) from the mean. A p value of <0.05 was 
considered significant for all comparisons. 
 
3. Results  
  
The study group consisted of 12 volunteers with an average age of 26.0±2.3 (range 
23-32) years (9 men and 3 women). Their body weight was 71.60 ±6.8 kg with a 
height of 172.8±5.6 cm and body mass index of 24.0±1.6 kg/m2.  There were no 
smokers in the study group and no subjects took any regular medications other than 
the oral contraceptive pill. There was no significant change in the LLS scores with 
increasing HA (p=0.16) and no cases of acute mountain sickness, although increasing 
altitude did lead to a significant fall in oxygen saturations (97.9±0.7% at baseline vs 
92.9±1.2% at 3600m) and heart rate (62.3±9.4 at baseline vs 74.8±12.3/minute at 
3600m) (table 1).  There were only two subjects with a LLS score of 3 and no LLS 
scores >3. There was no change in the HRV score with increasing LLS (figure 1; 
p=0.52) 
 
There was no significant change in the RMSSD-derived HRV values across all the 
seven altitudes with either the ithlete™ (P=0.3) or the CheckMyHeart™ Device 
(p=0.19) (figure 2). Further, there were no significant differences in RMSSD-derived 
HRV between the ithelte™™ and CheckMyHeart™ Device at any of the seven 
altitudes (p=0.47). 
 
There was a significant correlation between the first and second readings of the 
Ithlete™ taken at the end of one and five minutes (r=0.89; 0.82-0.93; coefficient of 
variation 5.5%). The first (r=0.80; 0.70-0.87: p<0.0001) and second (r=0.83 95% 
confidence interval: 0.74-0.89) ithlete™ HRV readings both strongly correlated with 
the five minute acquired CheckMyHeart™ HRV scores. However, the strongest 
correlation between the ithlete™ with the CheckMyHeart™ was obtained when the 
average of the two ithlete™ readings were used (r=0.86; 0.79 to 0.91) (figure 3).  
  
 
On Bland-Altman comparisons of the two methods of HRV assessment the values for 
RMSSD derived HRV were consistently but non-significantly higher with averaged 
ithlete™ than with the CheckMyHeart™ device (mean difference [bias] 1.8l; 95% 
limit of agreement -12.3 to 8.5) (figure 4).  
 
4. Discussion and Conclusions  
To the authors knowledge this is the first study to evaluate HRV at HA using two 
differing methods of HRV assessment. In this study the ithlete™ smart phone HRV 
application using a chest-borne heart rate sensor was compared with that of the 
CheckMyHeart™  electrocardiograph derived system over 55 second and five minute 
recordings respectively. The overall agreement between methods was reasonably 
good across the differing altitudes. HRV readings were consistently, though non-
significantly higher with the ithlete™ than with the CheckMyHeart™ System.  
 
The rational for this study was clear. HRV has evolved as an increasingly useful tool 
to assess physical and mental fitness (da Silva et al., 2015). However, traditional HRV 
assessments require at least five minutes of data recording, are more expensive and 
provide a plethora of highly complex time and frequency domain derived data  
undermining their applicability for everyday use. The ithlete™ circumvents these 
issues by providing an easy to understand intuitive RMSSD derived HRV reading 
obtained over 55 seconds which can be recorded to a mobile phone or portable tablet 
(Flatt and Esco., 2013). In the only previous comparative study to compare the 
ithlete™ to a reference HRV device a near perfect correlation between the ithlete™ 
and a five minute electrocardiography HRV device was observed in 25 healthy 
  
subjects at sea level (r = 0.99, p < 0.001) (Flatt and Esco 2013). On Bland Altman 
analysis the level of agreement was -2.57 to 2.63 above the constant bias (constant 
error) of -0.03. This is clearly much higher level of agreement than that obtained in 
our study. However, we believe this difference relates to the environmental and 
methodological differences between the two studies. The   previous ithlete™ 
validation study was performed in a temperature controlled laboratory at sea level. 
Conversely, our study was performed across several different time points and altitudes 
under very remote and challenging field conditions at HA. Secondly, the breathing 
prompts were only followed during the ithlete™ recordings within the five minute 
CheckMyHeart™ recording and not during the entire five minutes. This was because 
the CheckMyHeart™ device does not provide breathing prompts which were only 
available during the ithlete™ recording. This could explain the consistent, but 
marginally higher, HRV values for the ithlete™. Whilst we could have maintained the 
breathing prompts for the non-ithlete™ recording periods we were eager to assess the 
comparative differences in the two devices under their directed use. The subjects were 
instructed to undertake slow relaxed breathing during the non-ithlete™ 
CheckMyHeart™ recording periods. 
 
In this study we aimed to assess the utility and validity of a more simplified measure 
of HRV at HA as there has been accumulating data to suggest that hypoxia and HA 
lead to a reduction in HRV with a reduction in parasympathetic activity and a relative 
increase in sympathetic activity (Chen et al., 2008; Botek et al., 2015). In these 
previous studies the ascents were far more dramatic and rapid than in our current 
study which more closely reflects a real life HA trek. For example,  in a previous 
study of 27 volunteers Chen et al noted significant changes in several time and 
  
frequency domain  measures of HRV but their ascent was from 555 to 3180m in a 
cable car in <3 hours (Chen et al., 2008). And in another study Botek et al noted 
significant changes in HRV following abrupt exposure to normobaric hypoxia 
(FiO2=9.6%) which is a degree of hypoxia akin to that of >4000m (Botek et al.; 
2015). There is some data to suggest that changes in HRV may be linked or even 
predictive of AMS though this still remains controversial (Lanfranchi  et al., 2005; 
Chen et al., 2008; Koehle et al., 2010; Willie et al., 2012; Song et al., 2013; Karinen 
et al., 2012). This has important clinical implications as travel to HA has significantly 
increased in the last 10 years and AMS affects >35% of persons traveling to altitudes 
>3000m (Croughs et al., 2014). Previous studies assessing HRV and its links to HA 
have been partly undermined by the relatively small sample size. Hence, the ability to 
utilise more portable HRV devices such as the ithlete™ or the CheckMyheart™ 
device may have competitive value over several other HRV platforms. Given the 
sensitivity of the RMSSD to changes in parasympathetic activity and its recognised 
alterations at HA this created another persuasive reason to further explore the validity 
of the ithlete™ at HA. RMSSD is just one of the many time domain measures of 
HRV (eg SDNN, SDANN, pNN50). However, all of these measurements of short-
term variation estimate high frequency variations in heart rate and have been shown to 
be highly correlated (Task Force., 1996).  
 
This study has several limitations that need to be acknowledged. The sample size of 
this study was small however as the subjects were studied at seven different altitudes 
this significantly increased the data which is larger than the vast majority of HA HRV 
studies to date.  The altitude achieved was moderate (with no reported cases of AMS) 
and hence the results cannot necessarily apply to much higher altitudes though the 
  
consistency of the data and good agreement across all seven altitudes is encouraging. 
Despite it obvious portability and simplicity, the ithlete™ only records one parameter 
of HRV. Whereas the CheckMyHeart™ and other electrocardiograph HRV devices 
which use five minute recordings are able to provide detailed frequency domain and  
power spectral analysis allowing a more in depth assessment of changes in autonomic 
tone and sympatho/vagal balance.  
 
In conclusion the ithlete™ HRV system is a ultraportable HRV assessment system 
utilising a 55 second recording that has shown a good correlation with a reference 
method of HRV using a five minute recording from  a surface ECG. It has potential 
clinical applicability for the study of HRV at HA and comparative data from larger 
studies would be helpful.   
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Table 1 Changes in Key physiological variables with changing altitude 
Altitude 1400m 1100m 1600m 2000m 2500m 3110m 3600m  
Heart rate/minute 62.3±9.4 62.8±12.7 64.9±14.1 64.6±13.9 67.6±13.1 69.8±12.1 74.8±12.3* 0.002 
Systolic blood 
pressure, mmHg 
131.6±13.2 122.8±11.2 121.8±10.8* 130.3±13.2 128.8±13.1 131.3±14.1 129.1±16.0 0.006 
Diastolic blood 
pressure, mmHg 
79.5±7.5 73.9±10.8 73.4±9.0 78.8±9.9 76.3±8.3 81.2±9.0 79.8±9.3 0.03 
LLS 0.1±0.3 0.6±0.9 0.6±0.5 0.5±0.7 0.3±0.7 0.9±1.0 0.6±0.8 0.16 
SpO2,% 97.9±0.7 98.0±1.0 96.8±1.2 97.0±1.3 95.4±1.2* 93.0±1.7* 92.9±1.2* <0.001 
SpO2, oxygen saturations; LLS, lake Louise Scores; * significance vs baseline 1400m on post hoc test.  
 
 
  
Legend for Figures 
Figure 1 Changes in the Heart Variability Score with increasing Lake Louise Scores.  
Figure 2 Paired changes in heart Rate Variability for the ithlete™ versus 
CheckMyHeart™ at high altitude  
Figure 3 Correlation between ithlete™ and CheckMyHeart™ Heart Variability Score 
at high altitude  
Figure 4 Bland-Altman plots comparing ithlete™ and CheckMyHeart™ Heart 
Variability Scores at high altitude. The mean bias and the 95% confidence interval of 
the bias (2 standard deviations) are shown.   
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Figure 4 Bland-Altman plots comparing ithlete™ and CheckMyHeart™ Heart 
Variability Scores at high altitude. The mean bias and the 95% confidence interval of 
the bias (2 standard deviations) are shown.   
 
